Cohort B of the Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter

Inclusion Criteria: * Adult aged 25-80 * Patient understands and has signed the study informed consent form * Patient has an angiographic documented Chronic Total Occlusion (i.e. \>3 months occlusion duration) showing distal TIMI flow 0, with a reference diameter of at least 2 millimeters. * Left ventricle ejection fraction \> 25% Exclusion Criteria: * Patient unable to give informed consent. * Elevated CK-MB or troponin at baseline * Patient is known or suspected not to tolerate the contrast agent * Chronic Total Occlusion is located in aorto-ostial location, SVG CTO, in-stent occlusion * Appearance of a fresh thrombus or intraluminal filling defects * Intolerance to Aspirin and/or inability to tolerate a second antiplatelet agent (Clopidogrel and Prasugrel and Ticagrelor) * Cardiac intervention within 4 weeks of the procedure * Severe renal insufficiency with eGFR\<30 ml/min/1.72 m2 * Congestive heart failure \[New York Heart Association (NYHA) Class III\\IV\] CSA Class IV * Life expectancy \< 2 years due to other illnesses * Acute or unstable medical disorder/disease that may cause a risk to patient, including: i. Recent myocardial infarction (MI) (within the past two weeks) ii. Significant anemia (e.g. hemoglobin \< 8.0 mg / dl) iii. Recent major cerebrovascular event (history of stroke or TIA within 1 month) iv. Severe uncontrolled systemic hypertension (e.g., \>180/100 mmHg) v. Unstable angina requiring emergent percutaneous trans-luminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG)